CY1108042T1 - Θεραπεια εντερικων καταστασεων με ν-2,3,3-τετραμεθυλδικυκλο[2.2.1]επταν-2-αμινη - Google Patents

Θεραπεια εντερικων καταστασεων με ν-2,3,3-τετραμεθυλδικυκλο[2.2.1]επταν-2-αμινη

Info

Publication number
CY1108042T1
CY1108042T1 CY20081100029T CY081100029T CY1108042T1 CY 1108042 T1 CY1108042 T1 CY 1108042T1 CY 20081100029 T CY20081100029 T CY 20081100029T CY 081100029 T CY081100029 T CY 081100029T CY 1108042 T1 CY1108042 T1 CY 1108042T1
Authority
CY
Cyprus
Prior art keywords
amine
eptan
tetramethyl
cycle
treatment
Prior art date
Application number
CY20081100029T
Other languages
English (en)
Inventor
John Devane
Original Assignee
Agi Therapeutics Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Research Limited filed Critical Agi Therapeutics Research Limited
Publication of CY1108042T1 publication Critical patent/CY1108042T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η παρούσα εφεύρεση κατευθύνεται σε μεθόδους και συνταγοποιήσεις για μείωση, ανακούφιση ή/και χειρισμό μη κανονικών αυξήσεων στη γαστρεντερική κινητικότητα και εντερικών καταστάσεων που προκαλούν αυτήν. Συμπεριλαμβάνονται μέθοδοι χρήσης Ν-2,2,3-τετραμεθυλδικυκλο-[2.1.1 ]επταν-2-αμίνης και συνταγοποιήσεις που περιλαμβάνουν Ν-2,2,3-τετραμεθυλδικυκλο-[2.1.1 ]επταν-2-αμίνη.
CY20081100029T 2003-03-14 2008-01-09 Θεραπεια εντερικων καταστασεων με ν-2,3,3-τετραμεθυλδικυκλο[2.2.1]επταν-2-αμινη CY1108042T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45452703P 2003-03-14 2003-03-14
EP04720110A EP1603544B1 (en) 2003-03-14 2004-03-12 Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo 2.2.1 heptan-2-amine

Publications (1)

Publication Number Publication Date
CY1108042T1 true CY1108042T1 (el) 2013-09-04

Family

ID=32990912

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100029T CY1108042T1 (el) 2003-03-14 2008-01-09 Θεραπεια εντερικων καταστασεων με ν-2,3,3-τετραμεθυλδικυκλο[2.2.1]επταν-2-αμινη

Country Status (17)

Country Link
US (1) US20040209961A1 (el)
EP (1) EP1603544B1 (el)
JP (1) JP2006520379A (el)
AT (1) ATE375152T1 (el)
AU (1) AU2004218899A1 (el)
CA (1) CA2518385A1 (el)
CY (1) CY1108042T1 (el)
DE (1) DE602004009414T2 (el)
DK (1) DK1603544T3 (el)
ES (1) ES2294480T3 (el)
MX (1) MXPA05009640A (el)
NO (1) NO20054670L (el)
NZ (1) NZ542260A (el)
PL (1) PL1603544T3 (el)
PT (1) PT1603544E (el)
WO (1) WO2004080446A1 (el)
ZA (1) ZA200507159B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224284A1 (en) * 2004-03-12 2007-09-27 John Devane Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
US20060182819A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Soap scent patch and treatment for muscle spasm and pain
US20060182818A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Transdermal patch and treatment for pain and discomfort
US20070108228A1 (en) * 2005-11-15 2007-05-17 Willam Kleyne Method and apparatus for flushing eyes and skin
US20080207766A1 (en) * 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
US8569381B2 (en) 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
WO2011041146A2 (en) * 2009-09-29 2011-04-07 Novartis Ag Dosage regimen of an s1p receptor modulator
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
WO2017176753A1 (en) 2016-04-04 2017-10-12 Omeza LLC Fish oil topical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034079A (en) * 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
WO1999017803A1 (en) * 1997-10-03 1999-04-15 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
DE69916492T3 (de) * 1998-12-07 2008-08-14 J. Dev Ltd., Athlone Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen
CA2393437C (en) * 1998-12-16 2009-12-15 University Of South Florida Exo-s-mecamylamine formulation and use in treatment
US6734215B2 (en) * 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders

Also Published As

Publication number Publication date
PT1603544E (pt) 2008-01-22
AU2004218899A1 (en) 2004-09-23
CA2518385A1 (en) 2004-09-23
DE602004009414T2 (de) 2008-07-24
MXPA05009640A (es) 2005-10-26
EP1603544B1 (en) 2007-10-10
DE602004009414D1 (de) 2007-11-22
ATE375152T1 (de) 2007-10-15
NZ542260A (en) 2009-03-31
DK1603544T3 (da) 2008-01-14
JP2006520379A (ja) 2006-09-07
US20040209961A1 (en) 2004-10-21
ES2294480T3 (es) 2008-04-01
WO2004080446A1 (en) 2004-09-23
NO20054670D0 (no) 2005-10-11
ZA200507159B (en) 2008-03-26
PL1603544T3 (pl) 2008-03-31
NO20054670L (no) 2005-12-13
EP1603544A1 (en) 2005-12-14
WO2004080446B1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
CY1108042T1 (el) Θεραπεια εντερικων καταστασεων με ν-2,3,3-τετραμεθυλδικυκλο[2.2.1]επταν-2-αμινη
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
MXPA00011422A (es) Derivados de bencimidazol como moduladores de ige.
ATE458731T1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
ATE358117T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
ATE509917T1 (de) Gamma-secretase-inhibitoren
NO20052058D0 (no) Behandling av influensa.
MX249034B (es) Amidinas de tiofeno novedosas, composiciones de las mismas, y metodos para tratar enfermedades y condiciones mediadas por el complemento.
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE417616T1 (de) Behandlung von mukositis
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
DK1532131T3 (da) Motilid-forbindelser
NO20060420L (no) 2-aminobenzoylderivater
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
NO20055582L (no) Preparater og fremgangsmater omfattende gastrinforbindelser
ATE369136T1 (de) Therapeutische behandlung
ATE522601T1 (de) Varianten von antithrombin iii
DE502004012196D1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
DE60223086D1 (de) Modifikator für polymilchsäure und den modifikator enthaltende polymilchsäurezusammensetzung
DE60322983D1 (de) Pflanzliche zusammensetzung zur behandlung von gastrointestinalen erkrankungen
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
ATE299151T1 (de) Sequenzvarianten des menschlichen beta-1- adrenozeptorgens und ihre verwendung